In the summer 2024 issue of International Clinical Trials, Ellipses Pharma’s Head of Global Drug Development Professor Tobi Arkenau discusses our unique approach to using Ellipses’ unique Scientific Affairs Group to overcome challenges in oncological clinical trials.
Read the full article here.
About Ellipses Pharma Limited
Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimise the time it takes to advance lead products through clinical trials and reach patients.
For more information contact us: media@ellipses.life
